Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease:: peripheral inflammation or signals from the brain?

被引:333
|
作者
Licastro, F
Pedrini, S
Caputo, L
Annoni, G
Davis, LJ
Ferri, C
Casadei, V
Grimaldi, LME
机构
[1] Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy
[2] Osped Maggiore, IRCCS, Milan, Italy
[3] Univ Milan, Geriatr Clin, Milan, Italy
[4] Univ Milan, Hosp San Raffaele, DIBIT, Dept Neurol, Milan, Italy
关键词
Alzheimer's disease; plasma IL-1; IL-6; ACT; cognitive impairment;
D O I
10.1016/S0165-5728(99)00226-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Plasma concentrations of interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), C reactive protein (CRP) and alpha-1-antichymotrypsin (ACT) in 145 patients with probable Alzheimer's disease (AD) and 51 non-demented controls were measured. To investigate the cellular activation of peripheral immune system, plasma levels of neopterin were also investigated. Plasma levels of IL-1 were detectable in 17 patients with AD (13%) and only in one control (2%) and average levels of IL-1 were higher in AD patients than in controls (p < 0.001). IL-6 plasma levels were detectable in a higher proportion of AD and controls (53% and 27%, respectively), and were increased in patients with AD (p < 0.001). Plasma levels of ACT were increased in patients with AD (p < 0.001) and CRP levels were in the normal range. Plasma levels of neopterin were slightly lower in AD patients than in controls, but differences were not statistically significant. No significant correlation was observed between IL-1 and IL-6 levels or neopterin and cytokine levels in plasma from AD patients. Plasma levels of ACT negatively correlated with cognitive performances, as assessed by the mini mental state examination (MMSE; R = -0.26, p < 0.02) and positively correlated with the global deterioration state (GDS) of AD patients (R = 0.30, p < 0.007). Present findings suggested that detectable levels of circulating cytokines and increased ACT might not be derived by activation of peripheral immune system of AD patients. Detection of these molecules might be used for monitoring the progression of brain inflammation associated with AD. (C) 2000 Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 50 条
  • [1] Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk
    Licastro, F
    Pedrini, S
    Ferri, C
    Casadei, V
    Govoni, M
    Pession, A
    Sciacca, FL
    Veglia, F
    Annoni, G
    Bonafe, M
    Olivieri, F
    Franceschi, C
    Grimaldi, LME
    [J]. ANNALS OF NEUROLOGY, 2000, 48 (03) : 388 - 391
  • [2] Fasting Blood Interleukin-1β and Interleukin-6 Levels as Predictors of Agitation in Patients with Alzheimer's Disease
    Noto, Hiroyuki
    Kambayashi, Yasuhiro
    Hara, Akinori
    Tsujiguchi, Hiromasa
    Yamada, Yohei
    Nakamura, Haruki
    Nguyen, Thao
    Hatta, Kotaro
    Honma, Tatsuya
    Konoshita, Tadashi
    Nakamura, Hiroyuki
    [J]. INTERNATIONAL JOURNAL OF GERONTOLOGY, 2021, 15 (03) : 255 - 259
  • [3] Increased systemic inflammatory interleukin-1β and interleukin-6 during agitation as predictors of Alzheimer's disease
    Honma, T.
    Hatta, K.
    Hitomi, Y.
    Kambayashi, Y.
    Hibino, Y.
    Konoshita, T.
    Nakamura, H.
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2013, 28 (03) : 233 - 241
  • [4] INTERLEUKIN-1 AND INTERLEUKIN-6 LEVELS IN CORNEAS OF KERATOCONUS PATIENTS
    BECKER, J
    SALLA, S
    DOHMEN, U
    REDBRAKE, C
    REIM, M
    [J]. VISION RESEARCH, 1995, 35 : 2312 - 2312
  • [5] Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease:: Interleukin-1β, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-α, the soluble tumor necrosis factor receptors I and III, and α1-antichymotrypsin
    Lanzrein, AS
    Johnston, CM
    Perry, VH
    Jobst, KA
    King, EM
    Smith, AD
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1998, 12 (03): : 215 - 227
  • [6] Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures
    Uludag, Irem Fatma
    Bilgin, Sule
    Zorlu, Yasar
    Tuna, Gamze
    Kirkali, Guldal
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2013, 22 (06): : 457 - 461
  • [7] Central noradrenergic system modulates plasma interleukin-6 production by peripheral interleukin-1
    Huang, QH
    Takaki, A
    Arimura, A
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1997, 273 (02) : R731 - R738
  • [8] Association of interleukin-1 and interleukin-6 levels in lateralized temporal epilepsy patients
    Varoglu, Asuman Orhan
    Alvarisli, Aysenur
    Keskin, Havva
    Erman, Hayriye
    [J]. JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2024, 74 (07) : 1255 - 1260
  • [9] Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate α1-antichymotrypsin expression in human cortical astrocytes
    Kordula, T
    Rydel, RE
    Brigham, EF
    Horn, F
    Heinrich, PC
    Travis, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (07) : 4112 - 4118
  • [10] Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
    BlumDegen, D
    Muller, T
    Kuhn, W
    Gerlach, M
    Przuntek, H
    Riederer, P
    [J]. NEUROSCIENCE LETTERS, 1995, 202 (1-2) : 17 - 20